hotspot -WSS

hotspot

author：hotspot 2025-09-03 14:39:18 - browse：6562

Bill Cassidy speaks with his palm facing upward during a hearing on prescription drug costs — politics coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — Republicans in Congress might try to use a technical maneuver to block the Biden administration from using so-called march-in rights to seize pharmaceutical patents and lower drug prices.

The Biden White House wants to ignore certain patents for inventions that were developed with government funding, at least in extenuating circumstances. Taxpayers have helped fund the research of a substantial number of drugs sold in the United States though the National Institutes of Health, so the proposal would let the government bring in generic drugmakers to make medicines even before their patents expire.

Until the Biden administration, the government refused to consider that an invention’s price could justify the “march in” maneuver. But the White House in December issued a draft framework for the NIH to more broadly use the power, including in cases where price is a concern.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Readout Newsletter: Illumina, CRISPR, Regeneron

WSS

U.K. officials, researchers try to ease path for bespoke genetic treatments

This gene therapy has record $4.25 million price. It's saved children.

Pfizer, Moderna say biotech, pharma drug development is a sprint

Sanofi CEO defends move to abandon profit guidance, boost research

Removing probiotics from the NICU could threaten preemies' health

Readout LOUD podcast, live from the STAT Breakthrough Summit East

knowledge

hotspot

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Extreme heat events are a public health emergency

In Memoriam: Notable people who died in 2023

Excited delirium, Elijah McClain, and emergency physicians

Moonlake's readout produced a cash windfall. Risks remain

CRISPR technology availability, affordability needs to be expanded

Malaria cases in Florida and Texas: Here’s what you need to know

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Psychedelics group wrestles with new pharma identity

FDA approves potent Eli Lilly obesity drug, Zepbound

hotspot

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Readout LOUD podcast, live from the STAT Breakthrough Summit East

6 surprising facts about sugar

FDA approves potent Eli Lilly obesity drug, Zepbound

Surgeons perform first xenotransplant using CRISPR'd pig kidney

focus

hotspot

Wikipedia

leisure time